

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	814	(544/320).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:13
L2	103	(514/273).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:08
L3	0	kazutoshi.inv. adj watanabe.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:15
L4	0	kazutoshi.inv. adj watanabe.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:15
L5	591	kazutoshi.inv. and watanabe.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:15
L6	3	kazutoshi.inv. and watanabe.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:23
L7	3	Fumiaki.inv. and uehara.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:25
L8	1	shinsuke.inv. and Hiki.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:26
L9	0	satoshi.inv. and yokoshima.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:27
L10	1	Yoshihiro.inv. and Usui.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:27
L11	1	Masahiro.inv. and okuyama.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:28

EAST Search History



L12	3	Aya.inv. and Shoda.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:28
L13	1	Keiichi.inv. and Aritomo.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:29
L14	0	Toshiyuki.inv. and Kohara.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:29
L15	0	Kenji.inv. and Fukunaga.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:29

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	814	(544/320).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:13
L2	103	(514/273).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:08
L3	0	kazutoshi.inv. adj watanabe.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:15
L4	0	kazutoshi.inv. adj watanabe.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:15
L5	591	kazutoshi.inv. and watanabe.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:15
L6	3	kazutoshi.inv. and watanabe.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:23
L7	3	Fumiaki.inv. and uehara.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:25
L8	1	shinsuke.inv. and Hiki.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:26
L9	0	satoshi.inv. and yokoshima.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:27
L10	1	Yoshihiro.inv. and Usui.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:27
L11	1	Masahiro.inv. and okuyama.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:28

EAST Search History

L12	3	Aya.inv. and Shoda.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:28
L13	1	Keiichi.inv. and Aritomo.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:29
L14	0	Toshiyuki.inv. and Kohara.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:29
L15	0	Kenji.inv. and Fukunaga.inv. and (1 or 2)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/16 10:29



chain nodes :

7 8 47

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15 17 18 19 20 21 22 24 25 26 27 28 29 30 31 32
33 34 35 36 37 38 39 40 41

chain bonds :

1-8 2-10 4-47 6-7

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15 17-18 17-22 18-19 19-20
20-21 21-22 24-25 24-29 25-26 26-27 27-28 28-29 30-31 30-35 31-32 32-33 33-34 34-35
36-37 36-41 37-38 38-39 39-40 40-41

exact/norm bonds :

1-2 1-6 1-8 2-3 2-10 3-4 4-5 4-47 5-6 6-7 10-11 10-15 11-12 12-13 13-14 14-15 17-18
17-22 18-19 19-20 20-21 21-22 24-25 24-29 25-26 26-27 27-28 28-29 30-31 30-35 31-32
32-33 33-34 34-35 36-37 36-41 37-38 38-39 39-40 40-41

isolated ring systems :

containing 1 : 10 : 17 : 24 : 30 : 36 :

G1:C,N

G2:[*1],[*2],[*3],[*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:CLASS10:Atom 11:Atom 12:Atom 13:Atom
14:Atom 15:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 24:Atom 25:Atom 26:Atom
27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:Atom 41:Atom 47:CLASS

Element Count :

Node 8: Limited

C,C1-15

10550,299

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * * * Welcome to STN International * * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 5 MAY 11 KOREAPAT updates resume
NEWS 6 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 7 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAplus and
USPATFULL/USPAT2
NEWS 8 MAY 30 The F-Term thesaurus is now available in CA/CAplus
NEWS 9 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 10 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 11 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12 JUL 11 CHEMSAFE reloaded and enhanced
NEWS 13 JUL 14 FSTA enhanced with Japanese patents
NEWS 14 JUL 19 Coverage of Research Disclosure reinstated in DWPI
NEWS 15 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 16 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 17 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 18 SEP 11 CA/CAplus enhanced with more pre-1907 records
NEWS 19 SEP 21 CA/CAplus fields enhanced with simultaneous left and right
truncation
NEWS 20 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 21 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 22 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 23 SEP 28 CEABA-VTB classification code fields reloaded with new
classification scheme

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

10550,299

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:56:05 ON 16 OCT 2006

=> file reg
COST IN U.S. DOLLARS

FULL ESTIMATED COST

| SINCE FILE
ENTRY | TOTAL
SESSION |
|---------------------|------------------|
| 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 08:56:14 ON 16 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 OCT 2006 HIGHEST RN 910448-76-9
DICTIONARY FILE UPDATES: 15 OCT 2006 HIGHEST RN 910448-76-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> Uploading C:\Program Files\Stnexp\Queries\10550299.str



chain nodes :

7 8 47

ring nodes :

| | | | | | | | | | | | | | | | | | | | | | |
|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|
| 1 | 2 | 3 | 4 | 5 | 6 | 10 | 11 | 12 | 13 | 14 | 15 | 17 | 18 | 19 | 20 | 21 | 22 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | | | | | | | | |

chain bonds :

1-8 2-10 4-47 6-7

ring bonds :

| | | | | | | | | | | | | | | | | | | | | |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--|--|--|--|--|--|--|--|
| 1-2 | 1-6 | 2-3 | 3-4 | 4-5 | 5-6 | 10-11 | 10-15 | 11-12 | 12-13 | 13-14 | 14-15 | 17-18 | | | | | | | | |
| 17-22 | 18-19 | 19-20 | 20-21 | 21-22 | 24-25 | 24-29 | 25-26 | 26-27 | 27-28 | 28-29 | 30-31 | | | | | | | | | |
| 30-35 | 31-32 | 32-33 | 33-34 | 34-35 | 36-37 | 36-41 | 37-38 | 38-39 | 39-40 | 40-41 | | | | | | | | | | |

exact/norm bonds :

| | | | | | | | | | | | | | | | | | | | | |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--|--|--|--|--|--|--|
| 1-2 | 1-6 | 1-8 | 2-3 | 2-10 | 3-4 | 4-5 | 4-47 | 5-6 | 6-7 | 10-11 | 10-15 | 11-12 | 12-13 | | | | | | | |
| 13-14 | 14-15 | 17-18 | 17-22 | 18-19 | 19-20 | 20-21 | 21-22 | 24-25 | 24-29 | 25-26 | 26-27 | | | | | | | | | |
| 27-28 | 28-29 | 30-31 | 30-35 | 31-32 | 32-33 | 33-34 | 34-35 | 36-37 | 36-41 | 37-38 | 38-39 | | | | | | | | | |
| 39-40 | 40-41 | | | | | | | | | | | | | | | | | | | |

isolated ring systems :

containing 1 : 10 : 17 : 24 : 30 : 36 :

G1:C,N

G2:[*1],[*2],[*3],[*4]

Match level :

10550,299

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom
32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom 40:Atom
41:Atom 47:CLASS
Element Count :
Node 8: Limited
C,C1-15

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam
SAMPLE SEARCH INITIATED 08:56:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 79 TO ITERATE


100.0% PROCESSED 79 ITERATIONS 34 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1047 TO 2113
PROJECTED ANSWERS: 331 TO 1029

L2 34 SEA SSS SAM L1

=> d scan

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[4-[3-(1-pyrrolidinyl)phenyl]-1-
piperidinyl] - (9CI)
MF C24 H28 N6 O




10550,299

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):33

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-[(2S,6R)-2,6-dimethyl-4-morpholinyl]phenyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI)
MF C26 H32 N6 O2


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-[(2-acetoxyethyl)ethyl]-1-piperazinyl]phenyl]-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI)
MF C28 H34 F N7 O3


Absolute stereochemistry.



L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(2,6-dimethoxyphenyl)-1-piperazinyl]-1-


10550,299

methyl- (9CI)
MF C21 H24 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4(3H)-Pyrimidinone, 2-[3-(3-chlorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI)
MF C20 H20 Cl N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4-chlorophenyl)-1-piperazinyl]-3-(1-methylethyl)-6-(4-pyridinyl)- (9CI)
MF C22 H24 Cl N5 O
CI COM


Absolute stereochemistry.



10550,299

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4(3H)-Pyrimidinone, 2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI)
MF C22 H20 F N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-(5-ethyl-1,2,4-oxadiazol-3-yl)phenyl]-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI)
MF C24 H24 F N7 O2

Absolute stereochemistry.




L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[3-[4-(1-piperazinyl)phenyl]-1-piperazinyl]- (9CI)
MF C23 H28 N8 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4(3H)-Pyrimidinone, 2-[3-(3,4-dichlorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI)
MF C20 H19 Cl2 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-1-methyl- (9CI)
MF C26 H26 N6 O2
CI COM


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10550,299

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4(3H)-Pyrimidinone, 2-[3-(4-bromophenyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI)
MF C21 H21 Br N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1H-Indole, 1-[[1-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-4-piperidinyl]carbonyl]- (9CI)
MF C24 H23 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [4,4'-Bipyrimidin]-6(1H)-one, 2-[4-[[4-(dimethylamino)phenyl]amino]-1-piperidinyl]-1-methyl- (9CI)
MF C22 H27 N7 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4(3H)-Pyrimidinone, 2-[(3S)-3-(2',4'-dichloro[1,1'-biphenyl]-4-yl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI)
MF C26 H23 Cl2 N5 O

10550,299


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4'-(1-methylethyl)[1,1'-biphenyl]-4-yl]-1-piperazinyl]- (9CI)
MF C29 H30 F N5 O

Absolute stereochemistry.




L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-1-methyl-, dihydrochloride (9CI)
MF C26 H26 N6 O2 . 2 Cl H

Absolute stereochemistry.



●2 HCl

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 4(3H)-Pyrimidinone, 2-[3-(2,6-dimethoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI)
 MF C22 H25 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 4(3H)-Pyrimidinone, 2-[(3S,5R)-3-(4-chlorophenyl)-5-methyl-1-piperazinyl]-3-ethyl-6-(4-pyridinyl)- (9CI)
 MF C22 H24 Cl N5 O
 CI COM


Absolute stereochemistry.

10550,299




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4 (3H)-Pyrimidinone, 2-[4-(6-fluoro-1H-indazol-3-yl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI)
MF C22 H21 F N6 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4 (3H)-Pyrimidinone, 2-[4-(3-fluorobenzoyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI)
MF C22 H21 F N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10550,299

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [4,4'-Bipyrimidin]-6(1H)-one, 2-[4-(2-benzoxazolyl)-1-piperidinyl]-1-methyl- (9CI)
MF C21 H20 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4(3H)-Pyrimidinone, 3-methyl-2-[3-[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]-1-piperazinyl]-6-(4-pyridinyl)- (9CI)
MF C27 H35 N7 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(3S)-3-[4-(4-phenyl-1-piperazinyl)phenyl]-1-piperazinyl]- (9CI)
MF C29 H32 N8 O
CI COM


Absolute stereochemistry.

10550,299




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(4-chlorophenyl)-1-piperazinyl]-1-methyl- (9CI)
MF C19 H19 Cl N6 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4(3H)-Pyrimidinone, 2-[4-[(5-chloro-2-thienyl)carbonyl]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI)
MF C20 H19 Cl N4 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4(3H)-Pyrimidinone, 3-methyl-2-[3-(2-methylphenyl)-1-piperazinyl]-6-(4-

10550,299


pyridinyl)- (9CI)
MF C21 H23 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4(3H)-Pyrimidinone, 2-[(3S)-3-(1,2-benzisoxazol-3-yl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI)
MF C22 H21 N5 O2

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclohexanecarboxamide, N-[4-[(3S)-1-[(4-(3-fluoro-4-pyridinyl)-1,6-dihydro-1-methyl-6-oxo-2-pyrimidinyl)-3-piperidinyl]phenyl]- (9CI)
MF C28 H32 F N5 O2

Absolute stereochemistry.

10550,299




L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1-Piperazinecarboxylic acid, 4-[4-[4-(1,6-dihydro-1-methyl-6-oxo[4,4'-bipyrimidin]-2-yl)-2-piperazinyl]phenyl]-, phenylmethyl ester (9CI)
MF C31 H34 N8 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4(3H)-Pyrimidinone, 2-[3-(2-fluoro-6-methoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI)
MF C21 H22 F N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-[(3R)-3-hydroxy-1-pyrrolidinyl]phenyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI)
MF C24 H28 N6 O2
CI COM


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 4(3H)-Pyrimidinone, 2-[3-[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]methyl]phenyl]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)-, trihydrochloride (9CI)
 MF C₂₈ H₃₆ N₆ O . 3 Cl H


Absolute stereochemistry.



● 3 HCl

10550,299

L2 34 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4(3H)-Pyrimidinone, 2-[4-(4-chlorobenzoyl)-1-piperidinyl]-3-methyl-6-(4-
pyridinyl)- (9CI)
MF C22 H21 Cl N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s 11 sss ful
FULL SEARCH INITIATED 08:57:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1459 TO ITERATE

100.0% PROCESSED 1459 ITERATIONS 604 ANSWERS
SEARCH TIME: 00.00.01

L3 604 SEA SSS FUL L1

| | SINCE FILE
ENTRY | TOTAL
SESSION |
|----------------------|---------------------|------------------|
| => file caplus | | |
| COST IN U.S. DOLLARS | | |
| FULL ESTIMATED COST | 167.38 | 167.59 |

FILE 'CAPLUS' ENTERED AT 08:57:10 ON 16 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Oct 2006 VOL 145 ISS 17
FILE LAST UPDATED: 15 Oct 2006 (20061015/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

10550,299

=> s 13
L4 7 L3

=> d 14 1-7 bib hitstr


L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:317348 CAPLUS
DN 144:370114
TI Preparation of pyrimidone derivatives as inhibitors of tau protein kinase
1 for treatment of neurodegenerative diseases
IN Watanabe, Kazutoshi; Fukunaga, Kenji; Kohara, Toshiyuki; Uehara, Fumiaki;
Hiki, Shinsuke; Yokoshima, Satoshi
PA Mitsubishi Pharma Corporation, Japan; Sanofi-Aventis
SO PCT Int. Appl., 232 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2006036015 | A2 | 20060406 | WO 2005-JP18497 | 20050929 |
| | WO 2006036015 | A3 | 20060601 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | JP 2004-313115 | A | 20040929 | | |
| OS | MARPAT 144:370114 | | | | |
| IT | 881916-39-8P | | | | |
| | RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrimidone derivs. as inhibitors of tau
protein kinase 1 for treatment of neurodegenerative diseases) | | | | |
| RN | 881916-39-8 CAPLUS | | | | |
| CN | 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4-(1-
pyrrolidinyl)phenyl]-1-piperazinyl]-, trihydrochloride (9CI) (CA INDEX
NAME) | | | | |

Absolute stereochemistry.



IT 881916-33-2P 881916-40-1P 881916-41-2P
 881916-43-4P 881916-49-0P 881916-50-3P
 881916-51-4P 881916-52-5P 881916-53-6P
 881916-54-7P 881916-55-8P 881916-68-3P
 881916-69-4P 881916-70-7P 881916-71-8P
 881916-72-9P 881916-73-0P 881916-74-1P
 881916-75-2P 881916-78-5P 881916-79-6P
 881916-80-9P 881916-81-0P 881916-82-1P
 881916-84-3P 881916-85-4P 881916-86-5P
 881916-87-6P 881916-93-4P 881916-94-5P
 881916-95-6P 881916-96-7P 881916-97-8P
 881916-99-0P 881917-03-9P 881917-04-0P
 881917-05-1P 881917-08-4P 881917-10-8P
 881917-12-0P 881917-13-1P 881917-14-2P
 881917-15-3P 881917-16-4P 881917-17-5P
 881917-18-6P 881917-19-7P 881917-20-0P
 881917-21-1P 881917-22-2P 881917-23-3P
 881917-24-4P 881917-26-6P 881917-28-8P
 881917-29-9P 881917-30-2P 881917-31-3P
 881917-32-4P 881917-33-5P 881917-34-6P
 881917-35-7P 881917-36-8P 881917-41-5P
 881917-42-6P 881917-43-7P 881917-44-8P
 881917-49-3P 881917-51-7P 881917-52-8P
 881917-53-9P 881917-54-0P 881917-55-1P
 881917-56-2P 881917-57-3P 881917-59-5P
 881917-60-8P 881917-68-6P 881917-69-7P
 881917-70-0P 881917-80-2P 881917-81-3P
 881917-82-4P 881918-75-8P 881918-76-9P
 881919-02-4P 881919-15-9P 881919-16-0P
 881919-17-1P 881919-18-2P 881919-19-3P
 881919-20-6P 881919-21-7P 881919-22-8P
 881919-25-1P 881919-26-2P 881919-53-5P
 881919-54-6P 881919-55-7P 881919-56-8P
 881919-58-0P 881919-60-4P 881919-62-6P
 881919-76-2P 881919-78-4P 881919-80-8P
 881919-81-9P 881922-10-7P 881922-11-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

10550,299


(Uses)

(drug candidate; preparation of pyrimidone derivs. as inhibitors of tau protein kinase 1 for treatment of neurodegenerative diseases)

RN 881916-33-2 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4-(4-morpholinyl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881916-40-1 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4-(1-piperidinyl)phenyl]-1-piperazinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

RN 881916-41-2 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]phenyl]-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl-, tetrahydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●4 HCl

RN 881916-43-4 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]phenyl]-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl-, tetrahydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●4 HCl

RN 881916-49-0 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4-(4-methyl-1-piperazinyl)phenyl]-1-piperazinyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)

10550,299

Absolute stereochemistry.




● 4 HCl

RN 881916-50-3 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4-(4-phenyl-1-piperazinyl)phenyl]-1-piperazinyl]-, tetrahydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● 4 HCl

RN 881916-51-4 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4-(1-pyrrolidinyl)phenyl]-1-piperazinyl]-, tetrahydrochloride
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 4 HCl

RN 881916-52-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4-[1,4'-bipiperidin]-1'-ylphenyl)-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl-, tetrahydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● 4 HCl

RN 881916-53-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-(dimethylamino)-1-piperidinyl]phenyl]-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl-, tetrahydrochloride
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 4 HCl

RN 881916-54-7 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-2-[(3S)-3-[4-(4-hydroxy-1-piperidinyl)phenyl]-1-piperazinyl]-3-methyl-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

RN 881916-55-8 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-2-[(3S)-3-[4-[(3R)-3-hydroxy-1-pyrrolidinyl]phenyl]-1-piperazinyl]-3-methyl-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881916-68-3 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-(cyclohexylmethylamino)phenyl]-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl-, trihydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

RN 881916-69-4 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-2-[(3S)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-3-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 881916-70-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-(dimethylamino)phenyl]-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●3 HCl


RN 881916-71-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[4-(3-fluoro-4-pyridinyl)-1,6-dihydro-1-methyl-6-oxo-2-pyrimidinyl]-2-piperazinyl]phenyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 881916-72-9 CAPLUS


CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[3-[4-(1-piperazinyl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 881916-73-0 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881916-74-1 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-2-[(3S)-3-[4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]-1-piperazinyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881916-75-2 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-[2-(acetyloxy)ethyl]-1-piperazinyl]phenyl]-1-piperazinyl-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 881916-78-5 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-2-[(3S)-3-[4-(3-hydroxy-1-pyrrolidinyl)phenyl]-1-piperazinyl]-3-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10550,299



RN 881916-79-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-[(3S,5R)-3,5-dimethyl-1-piperazinyl]phenyl]-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 881916-80-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-[(2S,6R)-2,6-dimethyl-4-morpholinyl]phenyl]-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 881916-81-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-(4-bromophenyl)-1-piperidinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 881916-82-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-(3-bromophenyl)-1-piperidinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 881916-84-3 CAPLUS
CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[4-[1-(1-pyrrolidinyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 881916-85-4 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881916-86-5 CAPLUS


CN [1,1'-Biphenyl]-4-carbonitrile, 4'-[{(2S)-4-[4-(3-fluoro-4-pyridinyl)-1,6-dihydro-1-methyl-6-oxo-2-pyrimidinyl]-2-piperazinyl}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 881916-87-6 CAPLUS


CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[4-[3-(1-pyrrolidinyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 881916-93-4 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 881916-94-5 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

10550,299


Absolute stereochemistry.



RN 881916-95-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4'-ethoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881916-96-7 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4-(2-methyl-2,8-diazaspiro[4.5]dec-8-yl)phenyl]-1-piperazinyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 4 HCl


RN 881916-97-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-(3'S)-[1,3'-bipyrrolidin]-1'-ylphenyl]-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A






RN 881916-99-0 CAPLUS
 CN 4(3H)-Pyrimidinone, 2-[4-(4-fluorophenyl)-1-piperidinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 881917-03-9 CAPLUS
 CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 881917-04-0 CAPLUS
 CN 3-Pyrrolidinecarboxamide, 1-[4-[(2S)-4-[4-(3-fluoro-4-pyridinyl)-1,6-dihydro-1-methyl-6-oxo-2-pyrimidinyl]-2-piperazinyl]phenyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881917-05-1 CAPLUS

CN 3-Pyrrolidinecarbonitrile, 1-[4-[(2S)-4-[4-(3-fluoro-4-pyridinyl)-1,6-dihydro-1-methyl-6-oxo-2-pyrimidinyl]-2-piperazinyl]phenyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881917-08-4 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-(cyclohexylmethylamino)phenyl]-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 881917-10-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(4-[1,1'-biphenyl]-2-yl-1-piperazinyl)-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




10550,299

RN 881917-12-0 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(2',4'-dimethoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881917-13-1 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(3',4'-dimethoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881917-14-2 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4'-chloro[1,1'-biphenyl]-4-yl)-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881917-15-3 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(2',4'-dichloro[1,1'-biphenyl]-4-yl)-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 881917-16-4 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(3',4'-dichloro[1,1'-biphenyl]-4-yl)-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881917-17-5 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4-(1,2,4-oxadiazol-3-yl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881917-18-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4'-(cyclopropylmethoxy)[1,1'-biphenyl]-4-yl]-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 881917-19-7 CAPLUS

10550,299

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4'-(1-methylethoxy)[1,1'-biphenyl]-4-yl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881917-20-0 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4'-butoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 881917-21-1 CAPLUS

CN Piperazine, 1-benzoyl-2-[4-(dimethylamino)phenyl]-4-[4-(3-fluoro-4-pyridinyl)-1,6-dihydro-1-methyl-6-oxo-2-pyrimidinyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10550,299




RN 881917-22-2 CAPLUS
CN Piperazine, 1-(2-chlorobenzoyl)-2-[4-(dimethylamino)phenyl]-4-[4-(3-fluoro-4-pyridinyl)-1,6-dihydro-1-methyl-6-oxo-2-pyrimidinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 881917-23-3 CAPLUS
CN Piperazine, 1-(3-chlorobenzoyl)-2-[4-(dimethylamino)phenyl]-4-[4-(3-fluoro-4-pyridinyl)-1,6-dihydro-1-methyl-6-oxo-2-pyrimidinyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881917-24-4 CAPLUS

CN Piperazine, 1-(4-chlorobenzoyl)-2-[4-(dimethylamino)phenyl]-4-[4-(3-fluoro-4-pyridinyl)-1,6-dihydro-1-methyl-6-oxo-2-pyrimidinyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881917-26-6 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4'-(methylthio)[1,1'-biphenyl]-4-yl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881917-28-8 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-(4'-methyl[1,1'-biphenyl]-4-yl)-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881917-29-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl]-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881917-30-2 CAPLUS


CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4'-(1-methylethyl)[1,1'-biphenyl]-4-yl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 881917-31-3 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 881917-32-4 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[4-[(3-trifluoromethyl)phenyl]amino]-1-piperidinyl- (9CI) (CA INDEX NAME)




RN 881917-33-5 CAPLUS


CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-2-[4-[(2-methoxyphenyl)amino]-1-piperidinyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 881917-34-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-[[4-(dimethylamino)phenyl]amino]-1-piperidinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 881917-35-7 CAPLUS
CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-2-[4-[(3-methoxyphenyl)amino]-1-piperidinyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 881917-36-8 CAPLUS
CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-2-[4-[(4-methoxyphenyl)amino]-1-piperidinyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 881917-41-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4'-amino[1,1'-biphenyl]-4-yl)-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10550,299



RN 881917-42-6 CAPLUS


CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 881917-43-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(4-bromophenyl)-1-piperidinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 881917-44-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-(dimethylamino)phenyl]-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10550,299




RN 881917-49-3 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-(4-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 881917-51-7 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-2-[3-[4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]-1-piperidinyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 881917-52-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-[4-(dimethylamino)phenyl]-1-piperidinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 881917-53-9 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[3-[4-(4-morpholinyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 881917-54-0 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[3-[4-(1-piperidinyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 881917-55-1 CAPLUS


CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[3-[4-(4-methyl-1-piperazinyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 881917-56-2 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[3-[4-[4-(dimethylamino)-1-piperidinyl]phenyl]-1-piperidinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)

10550,299




RN 881917-57-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[1-[4-(3-fluoro-4-pyridinyl)-1,6-dihydro-1-methyl-6-oxo-2-pyrimidinyl]-3-piperidinyl]phenyl]-, phenylmethyl ester
(9CI) (CA INDEX NAME)




RN 881917-59-5 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-2-[4-[4-(2-hydroxyethyl)-1-piperazinyl]-1-piperidinyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 881917-60-8 CAPLUS


CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[3-[4-(1-piperazinyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 881917-68-6 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[4-[1-(3-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)

10550,299




RN 881917-69-7 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 881917-70-0 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[4-(4-phenyl-4H-1,2,4-triazol-3-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 881917-80-2 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[3-[4-(cyclohexylamino)phenyl]-1-piperidinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 881917-81-3 CAPLUS


10550,299

CN 4(3H)-Pyrimidinone, 2-[3-[4-(2,3-dihydro-1H-indol-1-yl)phenyl]-1-piperidinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 881917-82-4 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-[4-(cyclohexylmethylamino)phenyl]-1-piperidinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 881918-75-8 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[3-[4-(1-pyrrolidinyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 881918-76-9 CAPLUS


CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-2-[3-(4'-methoxy[1,1'-biphenyl]-4-yl)-1-piperidinyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 881919-02-4 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3R)-3-[4-(1-piperidinyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881919-15-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4-aminophenyl)-1-piperidinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 881919-16-0 CAPLUS

CN Acetamide, N-[4-[(3S)-1-[4-(3-fluoro-4-pyridinyl)-1,6-dihydro-1-methyl-6-oxo-2-pyrimidinyl]-3-piperidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10550, 299



RN 881919-17-1 CAPLUS

CN Thiourea, N-[4-[(3S)-1-[4-(3-fluoro-4-pyridinyl)-1,6-dihydro-1-methyl-6-oxo-2-pyrimidinyl]-3-piperidinyl]phenyl]-N'-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881919-18-2 CAPLUS

CN Urea, N-(2-fluorophenyl)-N'-[4-[(3S)-1-[4-(3-fluoro-4-pyridinyl)-1,6-dihydro-1-methyl-6-oxo-2-pyrimidinyl]-3-piperidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 881919-19-3 CAPLUS

10550,299

CN Carbamic acid, [4-[(3S)-1-[4-(3-fluoro-4-pyridinyl)-1,6-dihydro-1-methyl-6-oxo-2-pyrimidinyl]-3-piperidinyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881919-20-6 CAPLUS

CN Methanesulfonamide, N-[4-[(3S)-1-[4-(3-fluoro-4-pyridinyl)-1,6-dihydro-1-methyl-6-oxo-2-pyrimidinyl]-3-piperidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 881919-21-7 CAPLUS

CN Cyclohexanecarboxamide, N-[4-[(3S)-1-[4-(3-fluoro-4-pyridinyl)-1,6-dihydro-1-methyl-6-oxo-2-pyrimidinyl]-3-piperidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10550,299



RN 881919-22-8 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4-(4-methyl-1-piperazinyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881919-25-1 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3R)-3-phenyl-1-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881919-26-2 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-(5-ethyl-1,2,4-oxadiazol-3-yl)phenyl]-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 881919-53-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 881919-54-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-[3-(2-bromophenyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 881919-55-7 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[3-[3-(3-bromophenyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 881919-56-8 CAPLUS
 CN 4(3H)-Pyrimidinone, 2-[3-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 881919-58-0 CAPLUS
 CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-2-[3-[3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 881919-60-4 CAPLUS
 CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-2-[3-[3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 881919-62-6 CAPLUS
 CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-2-[3-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-3-methyl- (9CI) (CA INDEX NAME)


10550,299



RN 881919-76-2 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4-(1-piperidinyl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881919-78-4 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4-(4-methyl-1-piperazinyl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881919-80-8 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-2-[(3S)-3-[4-(4-hydroxy-1-piperidinyl)phenyl]-1-piperazinyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881919-81-9 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-2-[(3S)-3-[4-[(3R)-3-hydroxy-1-pyrrolidinyl]phenyl]-1-piperazinyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881922-10-7 CAPLUS


CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4-(1-piperidinyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 881922-11-8 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[3-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:817871 CAPLUS

DN 141:332207

TI Preparation of 2,3,6-trisubstituted-4-pyrimidones as tau protein kinase 1 inhibitors

IN Watanabe, Kazutoshi; Uehara, Fumiaki; Hiki, Shinsuke; Yokoshima, Satoshi; Usui, Yoshihiro; Okuyama, Masahiro; Shoda, Aya; Aritomo, Keiichi; Kohara, Toshiyuki; Fukunaga, Kenji

PA Mitsubishi Pharma Corporation, Japan; Sanofi-Synthelabo

SO PCT Int. Appl., 433 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2004085408 | A1 | 20041007 | WO 2004-JP4320 | 20040326 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, | | | | |

SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
 TD, TG
 AU 2004223987 A1 20041007 AU 2004-223987 20040326
 CA 2520027 AA 20041007 CA 2004-2520027 20040326
 EP 1608630 A1 20051228 EP 2004-723777 20040326
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
 BR 2004009042 A 20060328 BR 2004-9042 20040326
 CN 1764650 A 20060426 CN 2004-80008065 20040326
 JP 2006521370 T2 20060921 JP 2006-507692 20040326
 NO 2005004952 A 20051025 NO 2005-4952 20051025
 PRAI JP 2003-126021 A 20030326
 JP 2003-126022 A 20030326
 WO 2004-JP4320 W 20040326
 OS MARPAT 141:332207
 IT 769942-12-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 2,3,6-trisubstituted-4-pyrimidones as tau protein kinase 1 inhibitors for treatment and/or prevention of neurodegenerative diseases)
 RN 769942-12-3 CAPLUS
 CN 1-Piperazinecarboxylic acid, 3-(4-bromophenyl)-4-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-, phenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 769940-77-4P 769940-78-5P 769940-79-6P
 769940-80-9P 769940-81-0P 769940-83-2P
 769940-84-3P 769940-85-4P 769940-86-5P
 769940-87-6P 769940-88-7P 769940-89-8P
 769940-90-1P 769940-91-2P 769940-92-3P
 769940-93-4P 769940-95-6P 769940-96-7P
 769940-98-9P 769941-00-6P 769941-02-8P
 769941-04-0P 769941-06-2P 769941-07-3P
 769941-08-4P 769941-09-5P 769941-10-8P
 769941-11-9P 769941-12-0P 769941-13-1P
 769941-14-2P 769941-15-3P 769941-16-4P
 769941-17-5P 769941-18-6P 769941-19-7P
 769941-20-0P 769941-21-1P 769941-22-2P
 769941-23-3P 769941-24-4P 769941-25-5P

769941-26-6P 769941-27-7P 769941-28-8P
769941-29-9P 769941-30-2P 769941-31-3P
769941-32-4P 769941-33-5P 769941-34-6P
769941-35-7P 769941-37-9P 769941-40-4P
769941-42-6P 769941-43-7P 769941-44-8P
769941-45-9P 769941-46-0P 769941-47-1P
769941-48-2P 769941-49-3P 769941-50-6P
769941-51-7P 769941-52-8P 769941-53-9P
769941-54-0P 769941-55-1P 769941-56-2P
769941-57-3P 769941-58-4P 769941-59-5P
769941-60-8P 769941-61-9P 769941-62-0P
769941-63-1P 769941-64-2P 769941-65-3P
769941-66-4P 769941-67-5P 769941-68-6P
769941-69-7P 769941-70-0P 769941-71-1P
769941-72-2P 769941-73-3P 769941-74-4P
769941-75-5P 769941-76-6P 769941-77-7P
769941-78-8P 769941-79-9P 769941-80-2P
769941-81-3P 769941-82-4P 769941-83-5P
769941-84-6P 769941-85-7P 769941-86-8P
769941-87-9P 769941-88-0P 769941-89-1P
769941-90-4P 769941-91-5P 769941-92-6P
769941-93-7P 769941-94-8P 769941-95-9P
769941-96-0P 769941-97-1P 769941-98-2P
769941-99-3P 769942-00-9P 769942-01-0P
769942-02-1P 769942-03-2P 769942-04-3P
769942-05-4P 769942-06-5P 769942-07-6P
769942-08-7P 769942-09-8P 769942-10-1P
769942-11-2P 769942-13-4P 769942-14-5P
769942-15-6P 769942-16-7P 769942-17-8P
769942-18-9P 769942-19-0P 769942-20-3P
769942-21-4P 769942-22-5P 769942-23-6P
769942-24-7P 769942-25-8P 769942-26-9P
769942-27-0P 769942-28-1P 769942-29-2P
769942-30-5P 769942-31-6P 769942-32-7P
769942-33-8P 769942-34-9P 769942-35-0P
769942-36-1P 769942-37-2P 769942-38-3P
769942-39-4P 769942-40-7P 769942-41-8P
769942-42-9P 769942-44-1P 769942-46-3P
769942-47-4P 769942-48-5P 769942-49-6P
769942-50-9P 769942-51-0P 769942-52-1P
769942-53-2P 769942-54-3P 769942-55-4P
769942-56-5P 769942-57-6P 769942-58-7P
769942-59-8P 769942-60-1P 769942-61-2P
769942-62-3P 769942-63-4P 769942-64-5P
769942-65-6P 769942-66-7P 769942-67-8P
769942-68-9P 769942-69-0P 769942-70-3P
769942-71-4P 769942-72-5P 769942-73-6P
769942-74-7P 769942-75-8P 769942-76-9P
769942-77-0P 769942-78-1P 769942-79-2P
769942-80-5P 769942-81-6P 769942-82-7P
769942-83-8P 769942-84-9P 769942-85-0P
769942-86-1P 769942-87-2P 769942-88-3P
769942-89-4P 769942-90-7P 769942-91-8P
769942-92-9P 769942-93-0P 769942-94-1P
769942-95-2P 769942-96-3P 769942-97-4P
769942-98-5P 769942-99-6P 769943-00-2P
769943-01-3P 769943-02-4P 769943-03-5P
769943-04-6P 769943-05-7P 769943-06-8P
769943-07-9P 769943-08-0P 769943-09-1P
769943-10-4P 769943-11-5P 769943-12-6P
769943-13-7P 769943-14-8P 769943-15-9P

10550,299


769943-16-0P 769943-17-1P 769943-18-2P
769943-19-3P 769943-20-6P 769943-21-7P
769943-22-8P 769943-23-9P 769943-24-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,3,6-trisubstituted-4-pyrimidones as tau protein kinase 1 inhibitors for treatment and/or prevention of neurodegenerative diseases)


RN 769940-77-4 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[4-(phenylmethyl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769940-78-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(4-cyclohexyl-1-piperazinyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769940-79-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769940-80-9 CAPLUS


CN 2-Piperazinecarboxylic acid, 4-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-1-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 769940-81-0 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-(3-phenyl-1-piperazinyl)-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 769940-83-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(2-fluorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769940-84-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(3-fluorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769940-85-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(4-fluorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)


10550,299



● x HCl


RN 769940-86-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(4-fluorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769940-87-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(2-chlorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769940-88-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(3-chlorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769940-89-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(4-chlorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 769940-90-1 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3R)-3-(4-chlorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 769940-91-2 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3R)-3-(4-chlorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




●2 HCl

RN 769940-92-3 CAPLUS

10550,299


CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4-chlorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 769940-93-4 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(4-bromophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769940-95-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(2-methoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769940-96-7 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[3-(3-methoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



10550,299

RN 769940-98-9 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[3-(4-methoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 769941-00-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(4-methoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769941-02-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(2-ethoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769941-04-0 CAPLUS

CN Benzónitrile, 4-[4-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-2-piperazinyl]- (9CI) (CA INDEX NAME)




RN 769941-06-2 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[3-[4-(1-pyrrolidinyl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 769941-07-3 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[3-[4-(4-morpholinyl)phenyl]-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769941-08-4 CAPLUS


CN 4(3H)-Pyrimidinone, 3-methyl-2-[3-[4-(4-methyl-1-piperazinyl)phenyl]-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769941-09-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(2,5-dimethoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


10550,299




RN 769941-10-8 CAPLUS
CN 4 (3H)-Pyrimidinone, 2-[3-(2,6-dimethoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769941-11-9 CAPLUS
CN 4 (3H)-Pyrimidinone, 2-[3-(3,5-dimethoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769941-12-0 CAPLUS
CN 4 (3H)-Pyrimidinone, 2-[3-(4-fluoro-2-methoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769941-13-1 CAPLUS
CN 4 (3H)-Pyrimidinone, 2-[3-(4-fluoro-2-methoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl


RN 769941-14-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(2-fluoro-6-methoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769941-15-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(4-chloro-2-methoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769941-16-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(4-fluoro-2-methylphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 769941-17-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(5-bromo-2-methoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769941-18-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-[2-methoxy-4-(1-pyrrolidinyl)phenyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769941-19-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-[2-methoxy-5-(1-pyrrolidinyl)phenyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


10550,299




RN 769941-20-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(2,4-difluoro-6-methoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769941-21-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(2'-methoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769941-22-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(4'-methoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769941-23-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(4'-fluorobiphenyl-4-yl)-1-piperazinyl]-3-


10550,299

methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769941-24-4 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[3-(4-fluorophenyl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769941-25-5 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[3-(2-naphthalenyl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769941-26-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(2,3-dihydro-7-benzofuranyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




10550,299


RN 769941-27-7 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[4-methyl-3-(1-methylethyl)-1-piperazinyl]-
6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769941-28-8 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-(4-methyl-3-phenyl-1-piperazinyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769941-29-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(4-fluoro-2-methoxyphenyl)-4-methyl-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)





RN 769941-30-2 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[4-methyl-3-(1-naphthalenyl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769941-31-3 CAPLUS


10550,299

CN 4(3H)-Pyrimidinone, 2-[3-(4-fluoro-2-methoxyphenyl)-4-(phenylmethyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769941-32-4 CAPLUS

CN Piperazine, 1-acetyl-4-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-2-(4-fluoro-2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 769941-33-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[5-(2-methoxyphenyl)-3,3-dimethyl-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769941-34-6 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[3-(2-bromophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769941-35-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(3,4-dimethoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769941-37-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(3,4-dichlorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769941-40-4 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[(3S)-3-[4-(1-pyrrolidinyl)phenyl]-1-piperazinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10550,299



RN 769941-42-6 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-[4-(4-morpholinyl)phenyl]-1-piperazinyl]-6-(4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769941-43-7 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-[4-(4-methyl-1-piperazinyl)phenyl]-1-piperazinyl]-6-(4-pyridinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10550,299




● 4 HCl

RN 769941-44-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4-chlorophenyl)-1-piperazinyl]-3-ethyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 769941-45-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4-chlorophenyl)-1-piperazinyl]-3-(1-methylethyl)-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10550,299




●2 HCl

RN 769941-46-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(4-chlorophenyl)-5-methyl-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 769941-47-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[5-(4-chlorophenyl)-3,3-dimethyl-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 769941-48-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[5-(4-chlorophenyl)-3-(4-chlorophenyl)-5-methyl-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10550,299




●2 HCl

RN 769941-49-3 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]phenyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●4 HCl

RN 769941-50-6 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-[4-(1-piperidinyl)phenyl]-1-piperazinyl]-6-(4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

RN 769941-51-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]phenyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 4 HCl

RN 769941-52-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 769941-53-9 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 769941-54-0 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4-chlorophenyl)-5-methyl-1-piperazinyl]-3-ethyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 769941-55-1 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4-chlorophenyl)-5-methyl-1-piperazinyl]-3-(1-

10550,299


methylethyl)-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 769941-56-2 CAPLUS



CN 4(3H)-Pyrimidinone, 2-[5-(4-chlorophenyl)-3,3-dimethyl-1-piperazinyl]-3-ethyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 769941-57-3 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[5-(4-chlorophenyl)-3,3-dimethyl-1-piperazinyl]-3-(1-methylethyl)-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 769941-58-4 CAPLUS

CN 4(3H)-Pyrimidinone, 3-ethyl-2-[(3S)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 769941-59-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-3-(1-methylethyl)-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 769941-60-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4-cyclohexylphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 769941-61-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-(cyclohexylmethylamino)phenyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

RN 769941-62-0 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S,5R)-3-(4-chlorophenyl)-5-methyl-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 769941-63-1 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S,5R)-3-(4-chlorophenyl)-5-methyl-1-piperazinyl]-3-ethyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 769941-64-2 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S,5R)-3-(4-chlorophenyl)-5-methyl-1-piperazinyl]-3-(1-methylethyl)-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 769941-65-3 CAPLUS


CN 4(3H)-Pyrimidinone, 2-(4-[1,1'-biphenyl]-2-yl-1-piperazinyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

10550,299




RN 769941-66-4 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-(phenylmethyl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769941-67-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-[(4-chlorophenyl)methyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 769941-68-6 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-[4-(4-phenyl-1-piperazinyl)phenyl]-1-piperazinyl]-6-(4-pyridinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 4 HCl

RN 769941-69-7 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-[4-(1-piperidinyl)-1-piperazinyl]phenyl]-1-piperazinyl-6-(4-pyridinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 4 HCl

RN 769941-70-0 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-[4-(methylsulfonyl)phenyl]-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




10550,299

RN 769941-71-1 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(2S)-5-(4-chlorophenyl)-2-methyl-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 769941-72-2 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(2R)-5-(4-chlorophenyl)-2-methyl-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 769941-73-3 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-[4-(4-morpholinyl)phenyl]-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10550,299



RN 769941-74-4 CAPLUS


CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-[4-(4-morpholinyl)phenyl]-1-piperazinyl]-6-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 769941-73-3

CMF C24 H28 N6 O2


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 769941-75-5 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[(3S)-3-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-1-piperazinyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)

10550,299

Absolute stereochemistry.




● 4 HCl

RN 769941-76-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-[4-(dimethylamino)-1-piperidinyl]phenyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 4 HCl

RN 769941-77-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-(4-hydroxy-1-piperidinyl)phenyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

RN 769941-78-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-[(3R)-3-hydroxy-1-pyrrolidinyl]phenyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

RN 769941-79-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-(dimethylamino)phenyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10550,299



● 3 HCl


RN 769941-80-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[4-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-2-piperazinyl]phenyl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)



RN 769941-81-3 CAPLUS


CN 4(3H)-Pyrimidinone, 3-methyl-2-[3-[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769941-82-4 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769941-83-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-[2-(acetyloxy)ethyl]-1-piperazinyl]phenyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769941-84-6 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-[4-(1-piperazinyl)phenyl]-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769941-85-7 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-[4-(4-oxo-1-piperidinyl)phenyl]-1-

10550,299

piperazinyl]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 769941-86-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-(3-hydroxy-1-pyrrolidinyl)phenyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769941-87-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-[(3S,5R)-3,5-dimethyl-1-piperazinyl]phenyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10550,299



RN 769941-88-0 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-[(2S,6R)-2,6-dimethyl-4-morpholinyl]phenyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769941-89-1 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769941-90-4 CAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 4'-[(2S)-4-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-2-piperazinyl]- (9CI) (CA INDEX NAME)

10550,299


Absolute stereochemistry.



RN 769941-91-5 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[(3S)-3-[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769941-92-6 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[(3S)-3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10550,299

RN 769941-93-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4'-ethoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 769941-94-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4-(3'S)-[1,3'-bipyrrolidin]-1'-ylphenyl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A






RN 769941-95-9 CAPLUS
 CN 4(3H)-Pyrimidinone, 3-methyl-2-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769941-96-0 CAPLUS
 CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(2',4'-dimethoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769941-97-1 CAPLUS
 CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(3',4'-dimethoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10550, 299



RN 769941-98-2 CAPLUS

CN 4 (3H)-Pyrimidinone, 2-[(3S)-3-(4'-chlorobiphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769941-99-3 CAPLUS

CN 4 (3H)-Pyrimidinone, 2-[(3S)-3-(3',4'-dichlorobiphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769942-00-9 CAPLUS

CN 4 (3H)-Pyrimidinone, 2-[(3S)-3-(3',4'-dichlorobiphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


10550,299

Absolute stereochemistry.



RN 769942-01-0 CAPLUS


CN 4(3H)-Pyrimidinone, 3-methyl-2-[3-[4-(1,2,4-oxadiazol-3-yl)phenyl]-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769942-02-1 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-[4'-(phenylmethoxy)[1,1'-biphenyl]-4-yl]-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769942-03-2 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4'-(cyclopropylmethoxy)[1,1'-biphenyl]-4-yl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

10550,299


Absolute stereochemistry.



RN 769942-04-3 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-[4'-(1-methylethoxy)[1,1'-biphenyl]-4-yl]-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769942-05-4 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4'-butoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769942-06-5 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-[4'-(methylthio)[1,1'-biphenyl]-4-

10550,299

yl]-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769942-07-6 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-(4'-methyl[1,1'-biphenyl]-4-yl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769942-08-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10550,299

RN 769942-09-8 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-[4'-(1-methylethyl)[1,1'-biphenyl]-4-yl]-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769942-10-1 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4'-amino[1,1'-biphenyl]-4-yl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769942-11-2 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3S)-3-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769942-13-4 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(2S)-2-(4-bromophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769942-14-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 3-(4-bromophenyl)-4-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-, phenylmethyl ester, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769942-15-6 CAPLUS


CN 1-Piperazinecarboxylic acid, 3-(4-bromophenyl)-4-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-, 1,1-dimethylethyl ester, (3R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 769942-16-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[4-[1-(3-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




10550,299


RN 769942-17-8 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[4-[3-methyl-1-(2-pyridinyl)-1H-pyrazol-5-yl]-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-18-9 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[3-(phenylmethyl)-1-piperidinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769942-19-0 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-(3-phenyl-1-piperidinyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-20-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(2-fluorophenyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769942-21-4 CAPLUS


10550,299

CN 4(3H)-Pyrimidinone, 2-[3-(4-fluorophenyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-22-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(2-methoxyphenyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-23-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(4-methoxyphenyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769942-24-7 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[3-[4-(1-pyrrolidinylmethyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 769942-25-8 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[3-[4-(1-pyrrolidinylmethyl)phenyl]-1-piperidinyl]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 769942-24-7

CMF C₂₆ H₃₁ N₅ O




CM 2

CRN 110-17-8


CMF C₄ H₄ O₄

Double bond geometry as shown.




10550,299

RN 769942-26-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(1,2-benzisoxazol-3-yl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-27-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-28-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3R)-3-(1,2-benzisoxazol-3-yl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769942-29-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(1,2-benzisoxazol-3-yl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 769942-30-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(3-hydroxy-3-phenyl-1-piperidinyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-31-6 CAPLUS
CN 3-Piperidinecarbonitrile, 1-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 769942-32-7 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[4-(phenylmethyl)-1-piperidinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-33-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-[(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-34-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-[(4-fluorophenyl)methoxymethyl]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-35-0 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-(4-phenyl-1-piperidinyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-36-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-(4-fluorophenyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-37-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-(3,4-dichlorophenyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-38-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-(2-methoxyphenyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-39-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-(6-fluoro-3-benzofuranyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-40-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-41-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-(6-fluoro-1H-indazol-3-yl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-42-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-(2-benzoxazolyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769942-44-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-(2-benzothiazolyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-46-3 CAPLUS
CN 2(3H)-Benzothiazolone, 3-[1-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 769942-47-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-[(4-fluorophenyl)amino]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

10550,299




RN 769942-48-5 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[4-(methylphenylamino)-1-piperidinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-49-6 CAPLUS

CN Acetamide, N-[1-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-4-piperidinyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 769942-50-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(4-hydroxy-4-phenyl-1-piperidinyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-51-0 CAPLUS

CN 4-Piperidinecarbonitrile, 1-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




10550,299

RN 769942-52-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(4-acetyl-4-phenyl-1-piperidinyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-53-2 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[(3R)-3-[4-(1-pyrrolidinylmethyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 769942-54-3 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[(3S)-3-[4-(1-pyrrolidinylmethyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769942-55-4 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[(3R)-3-[4-(1-

10550,299

pyrrolidinylmethyl)phenyl]-1-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 769942-56-5 CAPLUS


CN Pyrrolidine, 1-[4-[1-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-3-piperidinyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 769942-57-6 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[(3S)-3-[4-(1-pyrrolidinylmethyl)phenyl]-1-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 769942-58-7 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[3-[4-(1-piperidinylmethyl)phenyl]-1-piperidinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769942-59-8 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[3-[4-[(cyclohexylmethylamino)methyl]phenyl]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769942-60-1 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-[4-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]methyl]phenyl]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 3 HCl


RN 769942-61-2 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-[4-[(cyclohexylethylamino)methyl]phenyl]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769942-62-3 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[3-[4-[[cyclohexyl(1-methylethyl)amino]methyl]phenyl]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769942-63-4 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]methyl]phenyl]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 3 HCl


RN 769942-64-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[4-(4-bromophenyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-65-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[4-(3-bromophenyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-66-7 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[4-[4-(1-pyrrolidinyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 769942-67-8 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[4-[3-(1-pyrrolidinyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 769942-68-9 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-69-0 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[4-[3-(trifluoromethyl)phenyl]amino]-1-piperidinyl]- (9CI) (CA INDEX NAME)


10550,299




RN 769942-70-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-[(4-(dimethylamino)phenyl)amino]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-71-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-[(3-methoxyphenyl)amino]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769942-72-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-[(4-methoxyphenyl)amino]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-73-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-[(2-methoxyphenyl)amino]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



10550,299


RN 769942-74-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[4-[(3-methoxyphenyl)methylamino]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-75-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[4-[(4-methoxyphenyl)methylamino]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-76-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[4-[(2-methoxyphenyl)methylamino]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-77-0 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[4-[[4-(dimethylamino)phenyl]methylamino]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-78-1 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[3-(4-bromophenyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-79-2 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-(4-oxo-1-piperidinyl)-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 769942-80-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-[4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-81-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-[4-(dimethylamino)phenyl]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-82-7 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[3-[4-(4-morpholinyl)phenyl]-1-piperidinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-83-8 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[3-[4-(1-piperidinyl)phenyl]-1-piperidinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769942-84-9 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[3-[4-(4-methyl-1-piperazinyl)phenyl]-1-piperidinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-85-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-[4-[4-(dimethylamino)-1-piperidinyl]phenyl]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-86-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[1-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-3-piperidinyl]phenyl]-, phenylmethyl ester (9CI)


(CA INDEX NAME)




RN 769942-87-2 CAPLUS
 CN 4(3H)-Pyrimidinone, 3-methyl-2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-88-3 CAPLUS
 CN 4(3H)-Pyrimidinone, 2-[4-[4-(2-hydroxyethyl)-1-piperazinyl]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-89-4 CAPLUS
 CN 4(3H)-Pyrimidinone, 3-methyl-2-[3-[4-(1-piperazinyl)phenyl]-1-piperidinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-90-7 CAPLUS
 CN 4(3H)-Pyrimidinone, 2-[4-[(2-methoxyphenyl)methyl]amino]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-91-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-[(4-methoxyphenyl)methyl]amino]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-92-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-[(2-(2-methoxyphenyl)ethyl)amino]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769942-93-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-[(2-(4-methoxyphenyl)ethyl)amino]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-94-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-[[[4-(dimethylamino)phenyl]methyl]amino]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



10550,299


RN 769942-95-2 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-1-piperidinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769942-96-3 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[4-(4-phenyl-4H-1,2,4-triazol-3-yl)-1-piperidinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769942-97-4 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[3-[4-(2,3-dihydro-1H-indol-1-yl)phenyl]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769942-98-5 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[3-[4-(cyclohexylamino)phenyl]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

10550,299




RN 769942-99-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-[4-(cyclohexylmethylamino)phenyl]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769943-00-2 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(2-fluorophenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769943-01-3 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(3-fluorophenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769943-02-4 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(4-fluorophenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)

10550,299




RN 769943-03-5 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(4-fluorophenyl)-1-piperazinyl]-1-methyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 769943-04-6 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(2-chlorophenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769943-05-7 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(3-chlorophenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769943-06-8 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(4-chlorophenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)


10550,299




RN 769943-07-9 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(4-bromophenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769943-08-0 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(2-methoxyphenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769943-09-1 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(3-methoxyphenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769943-10-4 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(4-methoxyphenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)


10550,299




RN 769943-11-5 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(2-ethoxyphenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769943-12-6 CAPLUS
CN Benzonitrile, 4-[4-(1,6-dihydro-1-methyl-6-oxo[4,4'-bipyrimidin]-2-yl)-2-piperazinyl]- (9CI) (CA INDEX NAME)



RN 769943-13-7 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[3-[4-(1-pyrrolidinyl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 769943-14-8 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[3-[4-(4-morpholinyl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 769943-15-9 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[3-[4-(4-methyl-1-piperazinyl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 769943-16-0 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(2,5-dimethoxyphenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769943-17-1 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(2,6-dimethoxyphenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769943-18-2 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(4-fluoro-2-methoxyphenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)

10550,299



RN 769943-19-3 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(4-fluoro-2-methoxyphenyl)-1-piperazinyl]-1-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 769943-20-6 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(2-fluoro-6-methoxyphenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769943-21-7 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(4-chloro-2-methoxyphenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769943-22-8 CAPLUS


10550,299

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(5-bromo-2-methoxyphenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769943-23-9 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-[2-methoxy-4-(1-pyrrolidinyl)phenyl]-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769943-24-0 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-[2-methoxy-5-(1-pyrrolidinyl)phenyl]-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)



IT 769943-25-1P 769943-26-2P 769943-27-3P
769943-28-4P 769943-29-5P 769943-30-8P
769943-31-9P 769943-32-0P 769943-33-1P
769943-34-2P 769943-35-3P 769943-36-4P
769943-37-5P 769943-38-6P 769943-39-7P
769943-40-0P 769943-41-1P 769943-42-2P
769943-43-3P 769943-44-4P 769943-45-5P
769943-46-6P 769943-47-7P 769943-48-8P

10550,299

769943-49-9P 769943-50-2P 769943-51-3P
769943-52-4P 769943-53-5P 769943-54-6P
769943-55-7P 769943-56-8P 769943-57-9P
769943-58-0P 769943-59-1P 769943-60-4P
769943-61-5P 769943-62-6P 769943-63-7P
769943-64-8P 769943-65-9P 769943-66-0P
769943-67-1P 769943-68-2P 769943-69-3P
769943-70-6P 769943-71-7P 769943-72-8P
769943-73-9P 769943-75-1P 769943-76-2P
769943-78-4P 769943-80-8P 769943-82-0P
769943-84-2P 769943-86-4P 769943-87-5P
769943-88-6P 769943-89-7P 769943-90-0P
769943-91-1P 769943-92-2P 769943-93-3P
769943-94-4P 769943-95-5P 769943-96-6P
769943-97-7P 769943-98-8P 769943-99-9P
769944-00-5P 769944-01-6P 769944-02-7P
769944-03-8P 769944-04-9P 769944-05-0P
769944-06-1P 769944-07-2P 769944-08-3P
769944-09-4P 769944-10-7P 769944-11-8P
769944-12-9P 769944-13-0P 769944-14-1P
769944-15-2P 769944-16-3P 769944-17-4P
769944-18-5P 769944-19-6P 769944-20-9P
769944-21-0P 769944-22-1P 769944-23-2P
769944-24-3P 769944-25-4P 769944-26-5P
769944-27-6P 769944-28-7P 769944-29-8P
769944-30-1P 769944-31-2P 769944-32-3P
769944-33-4P 769944-34-5P 769944-88-9P
769944-89-0P 769944-90-3P 769944-91-4P
769944-92-5P 769944-93-6P 769944-94-7P
769944-95-8P 769944-96-9P 769944-97-0P
769944-98-1P 769944-99-2P 769945-00-8P
769945-01-9P 769945-02-0P 769945-03-1P
769945-04-2P 769945-05-3P 769945-06-4P
769945-07-5P 769945-08-6P 769945-09-7P
769945-10-0P 769945-11-1P 769945-12-2P
769945-13-3P 769945-14-4P 769945-15-5P
769945-16-6P 769945-17-7P 769945-18-8P
769945-19-9P 769945-20-2P 769945-21-3P
769945-22-4P 769945-23-5P 769945-24-6P
769945-25-7P 769945-26-8P 769945-27-9P
769945-28-0P 769945-29-1P 769945-30-4P
769945-31-5P 769945-32-6P 769945-33-7P
769945-34-8P 770732-68-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,3,6-trisubstituted-4-pyrimidones as tau protein kinase 1 inhibitors for treatment and/or prevention of neurodegenerative diseases)

RN 769943-25-1 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one,.2-[3-(2,4-difluoro-6-methoxyphenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)

10550,299




RN 769943-26-2 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(2'-methoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769943-27-3 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(4'-methoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769943-28-4 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769943-29-5 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[3-(2-naphthalenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

10550,299





RN 769943-30-8 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(2,3-dihydro-6-benzofuranyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769943-31-9 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(4-fluoro-2-methoxyphenyl)-4-(phenylmethyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769943-32-0 CAPLUS


CN Piperazine, 1-acetyl-4-(1,6-dihydro-1-methyl-6-oxo[4,4'-bipyrimidin]-2-yl)-2-(4-fluoro-2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 769943-33-1 CAPLUS


10550,299

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(4-fluoro-2-methoxyphenyl)-1-methyl-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769943-34-2 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(3,4-dimethoxyphenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769943-35-3 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(4-chlorophenyl)-1-piperazinyl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 769943-36-4 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3R)-3-(4-chlorophenyl)-1-piperazinyl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10550,299



●2 HCl


RN 769943-37-5 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-(4-methyl-1-piperazinyl)- (9CI)
(CA INDEX NAME)




RN 769943-38-6 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[4-(2-hydroxyethyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769943-39-7 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[4-(1-methylethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 769943-40-0 CAPLUS


10550,299

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-(3,5-dimethyl-1-piperazinyl)-1-methyl-
(9CI) (CA INDEX NAME)




RN 769943-41-1 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(3,4-dichlorophenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769943-42-2 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(3-bromophenyl)-1-piperazinyl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 769943-43-3 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3R)-3-(4-chlorophenyl)-5-oxo-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769943-44-4 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(3R)-3-[4-(1-pyrrolidinyl)phenyl]-1-piperazinyl]-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769943-45-5 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(3S)-3-[4-(4-morpholinyl)phenyl]-1-piperazinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

RN 769943-46-6 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(3S)-3-[4-(4-methyl-1-piperazinyl)phenyl]-1-piperazinyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 4 HCl

RN 769943-47-7 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 769943-48-8 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]phenyl]-1-piperazinyl]-1-methyl-, tetrahydrochloride (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 769943-49-9 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-[4-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]phenyl]-1-piperazinyl]-1-methyl-, tetrahydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




●4 HCl

RN 769943-50-2 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 769943-51-3 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(4-cyclohexylphenyl)-1-piperazinyl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10550,299



●2 HCl

RN 769943-52-4 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-(4-[1,1'-biphenyl]-2-yl-1-piperazinyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 769943-53-5 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(3S)-3-(phenylmethyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 769943-54-6 CAPLUS

10550,299

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-[(4-chlorophenyl)methyl]-1-piperazinyl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 769943-55-7 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(3S)-3-[4-(1-piperidinyl)phenyl]-1-piperazinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

RN 769943-56-8 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(3S)-3-[4-(4-phenyl-1-piperazinyl)phenyl]-1-piperazinyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10550,299




● 4 HCl

RN 769943-57-9 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(4-[1,4'-bipiperidin]-1'-ylphenyl)-1-piperazinyl]-1-methyl-, tetrahydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 4 HCl

RN 769943-58-0 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[3-[4-(methylsulfonyl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 769943-59-1 CAPLUS

10550,299

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(3S)-3-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-1-piperazinyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 4 HCl

RN 769943-60-4 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-[4-[4-(dimethylamino)-1-piperidinyl]phenyl]-1-piperazinyl]-1-methyl-, tetrahydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 4 HCl

RN 769943-61-5 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-[4-(4-hydroxy-1-piperidinyl)phenyl]-1-piperazinyl]-1-methyl-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

RN 769943-62-6 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-[4-[(3R)-3-hydroxy-1-pyrrolidinyl]phenyl]-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769943-63-7 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-[4-(cyclohexylmethylamino)phenyl]-1-piperazinyl]-1-methyl-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HCl

RN 769943-64-8 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-[4-(dimethylamino)phenyl]-1-piperazinyl]-1-methyl-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●3 HCl

RN 769943-65-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[4-(1,6-dihydro-1-methyl-6-oxo[4,4'-bipyrimidin]-2-yl)-2-piperazinyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




10550,299

RN 769943-66-0 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(3S)-3-[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769943-67-1 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-[4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 769943-68-2 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[3-[4-(1-piperazinyl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 769943-69-3 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-[4-(3-hydroxy-1-pyrrolidinyl)phenyl]-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)

10550, 299


Absolute stereochemistry.



RN 769943-70-6 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-[4-[(3S,5R)-3,5-dimethyl-1-piperazinyl]phenyl]-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769943-71-7 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-[4-[(2S,6R)-2,6-dimethyl-4-morpholinyl]phenyl]-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769943-72-8 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(3S)-3-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769943-73-9 CAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 4'-[{(2S)-4-(1,6-dihydro-1-methyl-6-oxo[4,4'-bipyrimidin]-2-yl)-2-piperazinyl}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769943-75-1 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(3S)-3-[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]-1-piperazinyl]- (9CI) (CA INDEX

10550,299

NAME)


Absolute stereochemistry.



RN 769943-76-2 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(3S)-3-[4'-(trifluoromethyl)biphenyl-4-yl]piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769943-78-4 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(4'-ethoxybiphenyl-4-yl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10550,299

RN 769943-80-8 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-[4-(3'S)-[1,3'-bipyrrolidin]-1'-ylphenyl]-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 769943-82-0 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(2',4'-dimethoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10550,299




RN 769943-84-2 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(3',4'-dimethoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 769943-86-4 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(4'-chloro[1,1'-biphenyl]-4-yl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769943-87-5 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(2',4'-dichloro[1,1'-biphenyl]-4-yl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)

10550,299


Absolute stereochemistry.



RN 769943-88-6 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(3',4'-dichloro[1,1'-biphenyl]-4-yl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 769943-89-7 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[3-[4-(1,2,4-oxadiazol-3-yl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 769943-90-0 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(3S)-3-[4'-(1-methylethoxy)[1,1'-biphenyl]-4-yl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

10550,299


Absolute stereochemistry.



RN 769943-91-1 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(4'-butoxy[1,1'-biphenyl]-4-yl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769943-92-2 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(3S)-3-[4'-(methylthio)[1,1'-biphenyl]-4-yl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769943-93-3 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(3S)-3-(4'-methyl[1,1'-biphenyl]-

10550,299

4-yl)-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769943-94-4 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(3S)-3-[4'-(1-methylethyl)[1,1'-biphenyl]-4-yl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769943-95-5 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(4'-amino[1,1'-biphenyl]-4-yl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10550,299


RN 769943-96-6 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(2-bromophenyl)-1-piperazinyl]-1-methyl-
(9CI) (CA INDEX NAME)




RN 769943-97-7 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[3-(phenoxyethyl)-1-piperidinyl]-
(9CI) (CA INDEX NAME)



RN 769943-98-8 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(benzoyloxy)methyl]-1-piperidinyl-1-
methyl- (9CI) (CA INDEX NAME)




RN 769943-99-9 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(1,2-benzisoxazol-3-yl)-1-piperidinyl]-
1-methyl- (9CI) (CA INDEX NAME)



RN 769944-00-5 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(6-fluoro-1,2-benzisoxazol-3-yl)-1-
piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)


10550,299



RN 769944-01-6 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3R)-3-(1,2-benzisoxazol-3-yl)-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769944-02-7 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(1,2-benzisoxazol-3-yl)-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 769944-03-8 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[4-(4-fluorophenyl)-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769944-04-9 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[4-(6-fluoro-3-benzofuranyl)-1-

10550,299


piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769944-05-0 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[4-(5-methyl-3-benzofuranyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 769944-06-1 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769944-07-2 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769944-08-3 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[4-(2-benzoxazolyl)-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769944-09-4 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-(4-phenyl-1-piperidinyl)- (9CI)
(CA INDEX NAME)




RN 769944-10-7 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[3-[4-(1-pyrrolidinylmethyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 769944-11-8 CAPLUS


CN Pyrrolidine, 1-[4-[1-(1,6-dihydro-1-methyl-6-oxo[4,4'-bipyrimidin]-2-yl)-3-piperidinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 769944-12-9 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[1,4'-bipiperidin]-1'-yl-1-methyl- (9CI)
(CA INDEX NAME)



RN 769944-13-0 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[4-(4-bromophenyl)-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769944-14-1 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[4-(3-bromophenyl)-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769944-15-2 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[4-(1-pyrrolidinyl)phenyl]-1-


10550,299

piperidinyl]- (9CI) (CA INDEX NAME)




RN 769944-16-3 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[4-[3-(1-pyrrolidinyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 769944-17-4 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[4-[[4-(dimethylamino)phenyl]amino]-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769944-18-5 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[4-[(3-methoxyphenyl)amino]-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769944-19-6 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[4-[(4-methoxyphenyl)amino]-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769944-20-9 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[4-[(2-methoxyphenyl)amino]-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769944-21-0 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(4-bromophenyl)-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769944-22-1 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-[4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)



10550,299


RN 769944-23-2 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-[4-(dimethylamino)phenyl]-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769944-24-3 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[3-[4-(4-morpholinyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 769944-25-4 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[3-[4-(1-piperidinyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 769944-26-5 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[3-[4-(4-methyl-1-piperazinyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 769944-27-6 CAPLUS


10550,299

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-[4-[4-(dimethylamino)-1-piperidinyl]phenyl]-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769944-28-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[1-(1,6-dihydro-1-methyl-6-oxo[4,4'-bipyrimidin]-2-yl)-3-piperidinyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 769944-29-8 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 769944-30-1 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[4-[4-(2-hydroxyethyl)-1-piperazinyl]-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769944-31-2 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[3-[4-(1-piperazinyl)phenyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)

10550,299




RN 769944-32-3 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-[4-(cyclohexylamino)phenyl]-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769944-33-4 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-[4-(2,3-dihydro-1H-indol-1-yl)phenyl]-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769944-34-5 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-[4-(cyclohexylmethylamino)phenyl]-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769944-88-9 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[3-(4-chlorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769944-89-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(3-bromophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769944-90-3 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[3-(4-methylphenyl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769944-91-4 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[3-(3-methylphenyl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769944-92-5 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[3-(2-methylphenyl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769944-93-6 CAPLUS

CN Benzonitrile, 3-[4-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-2-piperazinyl]- (9CI) (CA INDEX NAME)




RN 769944-94-7 CAPLUS

CN Benzonitrile, 2-[4-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-2-piperazinyl]- (9CI) (CA INDEX NAME)




RN 769944-95-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(5-fluoro-2-methoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769944-96-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(4-fluoro-3-methoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769944-97-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4-fluoro-2-methoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769944-98-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3R)-3-(4-fluoro-2-methoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769944-99-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4-fluoro-2-methoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

10550,299




RN 769945-00-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(2-bromo-4-fluorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769945-01-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(2-chloro-6-fluorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769945-02-0 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[3-(2,4-difluorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769945-03-1 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(2,6-difluorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


10550,299




RN 769945-04-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(2,6-dichlorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769945-05-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(2,4-dimethoxyphenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769945-06-4 CAPLUS
CN Benzonitrile, 3-[4-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-2-piperazinyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 769945-07-5 CAPLUS
CN Benzonitrile, 4-[4-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-2-piperazinyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 769945-08-6 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[3-(2-benzofuranyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769945-09-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3S)-3-benzo[b]thien-2-yl-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769945-10-0 CAPLUS


CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[3-[4-(1-pyrrolidinylmethyl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

10550,299




RN 769945-11-1 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[3-[2-methyl-4-(1-pyrrolidinyl)phenyl]-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769945-12-2 CAPLUS


CN 4(3H)-Pyrimidinone, 2-(3-[1,1'-biphenyl]-4-yl-1-piperazinyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769945-13-3 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-(4-phenyl-1-piperazinyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

10550,299




RN 769945-14-4 CAPLUS
CN Piperazine, 1-benzoyl-4-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 769945-15-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4-fluoro-2-methoxyphenyl)-4-methyl-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769945-16-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3R)-3-(4-fluoro-2-methoxyphenyl)-4-methyl-1-piperazinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10550,299




RN 769945-17-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(3-fluorophenyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769945-18-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[3-(4-chlorophenyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 769945-19-9 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[3-(3-methoxyphenyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 769945-20-2 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-(3-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)


10550,299




RN 769945-21-3 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(3-bromophenyl)-1-piperazinyl]-1-methyl-
(9CI) (CA INDEX NAME)




RN 769945-22-4 CAPLUS
CN Benzonitrile, 3-[4-(1,6-dihydro-1-methyl-6-oxo[4,4'-bipyrimidin]-2-yl)-2-
piperazinyl]- (9CI) (CA INDEX NAME)



RN 769945-23-5 CAPLUS
CN Benzonitrile, 2-[4-(1,6-dihydro-1-methyl-6-oxo[4,4'-bipyrimidin]-2-yl)-2-
piperazinyl]- (9CI) (CA INDEX NAME)




RN 769945-24-6 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(5-fluoro-2-methoxyphenyl)-1-
piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 769945-25-7 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(4-fluoro-2-methoxyphenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769945-26-8 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3R)-3-(4-fluoro-2-methoxyphenyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769945-27-9 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[3-(1-naphthalenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

10550,299




RN 769945-28-0 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(2,3-dihydro-7-benzofuranyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769945-29-1 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(2-benzofuranyl)-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 769945-30-4 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[3-[4-(1-pyrrolidinylmethyl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

10550,299



RN 769945-31-5 CAPLUS


CN [4,4'-Bipyrimidin]-6(1H)-one, 2-(3-[1,1'-biphenyl]-4-yl-1-piperazinyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 769945-32-6 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(4-fluoro-2-methoxyphenyl)-4-methyl-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 769945-33-7 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3R)-3-(4-fluoro-2-methoxyphenyl)-4-methyl-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769945-34-8 CAPLUS
 CN 4-Piperidinecarbonitrile, 1-(1,6-dihydro-1-methyl-6-oxo[4,4'-bipyrimidin]-2-yl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 770732-68-8 CAPLUS
 CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4-chlorophenyl)-1-piperazinyl]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



●2 HCl

IT 769944-40-3P, 2-(1-(tert-Butoxycarbonyl)-2-(4-chlorophenyl)piperazin-4-yl)-3-methyl-6-(4-pyridyl)pyrimidin-4-one
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 2,3,6-trisubstituted-4-pyrimidones as tau protein kinase 1 inhibitors for treatment and/or prevention of neurodegenerative

diseases)
RN 769944-40-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 2-(4-chlorophenyl)-4-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


| L4 | ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN | | | |
|---|---|----------|------------------|----------|
| AN | 2003:356440 CAPLUS | | | |
| DN | 138:368904 | | | |
| TI | Preparation of 3-substituted 4-pyrimidones as tau protein kinase 1 inhibitors | | | |
| IN | Uehara, Fumiaki; Aritomo, Keiichi; Shoda, Aya; Hiki, Shinsuke; Okuyama, Masahiro; Usui, Yoshihiro; Ooizumi, Mitsuru; Watanabe, Kazutoshi; Yamakoshi, Koichi | | | |
| PA | Mitsubishi Pharma Corporation, Japan; Sanofi-Synthelabo | | | |
| SO | PCT Int. Appl., 153 pp.
CODEN: PIXXD2 | | | |
| DT | Patent | | | |
| LA | English | | | |
| FAN.CNT 2 | | | | |
| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
| ----- | ----- | ----- | ----- | ----- |
| PI WO 2003037888 | A1 | 20030508 | WO 2002-JP9685 | 20020920 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2460121 | AA | 20030508 | CA 2002-2460121 | 20020920 |
| EP 1427720 | A1 | 20040616 | EP 2002-772871 | 20020920 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| BR 2002012892 | A | 20040803 | BR 2002-12892 | 20020920 |
| CN 1556804 | A | 20041222 | CN 2002-818469 | 20020920 |
| JP 2005510506 | T2 | 20050421 | JP 2003-540169 | 20020920 |
| US 2005090490 | A1 | 20050428 | US 2003-489606 | 20020920 |
| NZ 531636 | A | 20051125 | NZ 2002-531636 | 20020920 |
| CN 1810802 | A | 20060802 | CN 2005-10097948 | 20020920 |
| ZA 2004001845 | A | 20050307 | ZA 2004-1845 | 20040305 |
| ZA 2004001850 | A | 20050307 | ZA 2004-1850 | 20040305 |
| NO 2004001600 | A | 20040616 | NO 2004-1600 | 20040420 |
| PRAI JP 2001-331674 | A | 20010921 | | |

10550,299

| | | | |
|-----|--|----|----------|
| JP | 2001-331675 | A | 20010921 |
| JP | 2001-331677 | A | 20010921 |
| JP | 2001-331678 | A | 20010921 |
| CN | 2002-818469 | A3 | 20020920 |
| WO | 2002-JP9685 | W | 20020920 |
| OS | MARPAT 138:368904 | | |
| IT | 521968-94-5P 521968-95-6P 521968-96-7P
521968-97-8P 521968-98-9P 521968-99-0P
521969-00-6P 521969-01-7P 521969-09-5P
521969-10-8P 521969-11-9P 521969-12-0P
521969-13-1P 521969-14-2P 521969-15-3P
521969-16-4P 521969-17-5P 521969-18-6P
521969-19-7P 521969-20-0P 521969-21-1P
521969-22-2P 521969-23-3P 521969-25-5P
521969-27-7P 521969-29-9P 521969-31-3P
521969-33-5P 521969-35-7P 521969-37-9P
521969-39-1P 521969-41-5P 521969-42-6P
521969-93-7P | | |
| RL: | PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | |
| | (preparation of 3-substituted 4-pyrimidones as tau protein kinase 1 inhibitors) | | |
| RN | 521968-94-5 CAPLUS | | |
| CN | 4(3H)-Pyrimidinone, 2-(3-benzoyl-1-piperidinyl)-3-methyl-6-(4-pyridinyl)-(9CI) (CA INDEX NAME) | | |




| | |
|----|--|
| RN | 521968-95-6 CAPLUS |
| CN | 4(3H)-Pyrimidinone, 2-[3-(4-fluorobenzoyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)-(9CI) (CA INDEX NAME) |




| | |
|----|---|
| RN | 521968-96-7 CAPLUS |
| CN | 4(3H)-Pyrimidinone, 2-[3-(4-methoxybenzoyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)-(9CI) (CA INDEX NAME) |


10550,299




RN 521968-97-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[3-(2-methoxybenzoyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 521968-98-9 CAPLUS
CN 3-Piperidinecarboxamide, 1-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 521968-99-0 CAPLUS
CN Quinoline, 1-[[1-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-3-piperidinyl]carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




10550,299


RN 521969-00-6 CAPLUS
CN Piperidine, 1-[[1-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-3-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 521969-01-7 CAPLUS
CN Morpholine, 4-[[1-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-3-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 521969-09-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(4-benzoyl-1-piperidinyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 521969-10-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-(2-fluorobenzoyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 521969-11-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-(3-fluorobenzoyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 521969-12-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-(4-fluorobenzoyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 521969-13-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-(2-methoxybenzoyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 521969-14-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-(3-methoxybenzoyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 521969-15-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-(4-methoxybenzoyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



10550,299


RN 521969-16-4 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[4-(3-chlorobenzoyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 521969-17-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[4-(4-chlorobenzoyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 521969-18-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[4-(4-bromobenzoyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 521969-19-7 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[4-(2,3-dimethoxybenzoyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 521969-20-0 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[4-(2,4-difluorobenzoyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


10550, 299




RN 521969-21-1 CAPLUS
CN 4 (3H)-Pyrimidinone, 2-[4-(3,4-difluorobenzoyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 521969-22-2 CAPLUS
CN 4 (3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[4-(2-thienylcarbonyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 521969-23-3 CAPLUS
CN 4 (3H)-Pyrimidinone, 2-[4-(2-furanylcarbonyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 521969-25-5 CAPLUS
CN 4 (3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[4-(2-pyridinylcarbonyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)

10550,299




RN 521969-27-7 CAPLUS

CN 1H-Indole, 1-[[1-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 521969-29-9 CAPLUS

CN Quinoline, 1-[[1-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-4-piperidinyl]carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 521969-31-3 CAPLUS


CN 1H-Indole, 1-[[1-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-4-piperidinyl]carbonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 521969-33-5 CAPLUS
CN Isoquinoline, 2-[[1-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-4-piperidinyl]carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 521969-35-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-[(5-chloro-2-thienyl)carbonyl]-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 521969-37-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-([1,1'-biphenyl]-4-ylcarbonyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 521969-39-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[4-([1,1'-biphenyl]-2-ylcarbonyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 521969-41-5 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[4-(1-naphthalenylcarbonyl)-1-piperidinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 521969-42-6 CAPLUS
 CN 4(3H)-Pyrimidinone, 2-[4-(4-fluoro-2-methoxybenzoyl)-1-piperidinyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 521969-93-7 CAPLUS
 CN 1H-Indole, 1-[[1-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]-3-piperidinyl]carbonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:261819 CAPLUS
 DN 138:287693
 TI Preparation of 6-pyrimidinyl 3-substituted-4-pyrimidones that inhibit tau protein kinase 1 useful against neurodegenerative diseases like Alzheimer's disease
 IN Uehara, Fumiaki; Aritomo, Keiichi; Shoda, Aya; Hiki, Shinsuke; Okuyama, Masahiro; Usui, Yoshihiro; Ooizumi, Mitsuru; Watanabe, Kazutoshi
 PA Mitsubishi Pharma Corporation, Japan; Sanofi-Synthelabo
 SO PCT Int. Appl., 135 pp.
 CODEN: PIXXD2
 DT Patent
 LA English


FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2003027080 | A1 | 20030403 | WO 2002-JP9684 | 20020920 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2460177 | AA | 20030403 | CA 2002-2460177 | 20020920 |
| | EP 1427709 | A1 | 20040616 | EP 2002-772870 | 20020920 |
| | EP 1427709 | B1 | 20051214 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| | BR 2002012893 | A | 20040803 | BR 2002-12893 | 20020920 |
| | CN 1555367 | A | 20041215 | CN 2002-818017 | 20020920 |
| | JP 2005510472 | T2 | 20050421 | JP 2003-530670 | 20020920 |
| | US 2005130967 | A1 | 20050616 | US 2003-489607 | 20020920 |
| | AT 312827 | E | 20051215 | AT 2002-772870 | 20020920 |
| | NZ 531637 | A | 20051223 | NZ 2002-531637 | 20020920 |
| | ES 2256540 | T3 | 20060716 | ES 2002-2772870 | 20020920 |
| | CN 1810802 | A | 20060802 | CN 2005-10097948 | 20020920 |
| | ZA 2004001845 | A | 20050307 | ZA 2004-1845 | 20040305 |
| | ZA 2004001850 | A | 20050307 | ZA 2004-1850 | 20040305 |
| | NO 2004001604 | A | 20040617 | NO 2004-1604 | 20040420 |
| | HK 1068608 | A1 | 20060721 | HK 2004-109693 | 20041207 |
| PRAI | JP 2001-331674 | A | 20010921 | | |
| | JP 2001-331675 | A | 20010921 | | |
| | JP 2001-331676 | A | 20010921 | | |
| | JP 2001-331678 | A | 20010921 | | |
| | JP 2001-331677 | A | 20010921 | | |
| | CN 2002-818469 | A3 | 20020920 | | |
| | WO 2002-JP9684 | W | 20020920 | | |
| OS | MARPAT 138:287693 | | | | |
| IT | 503860-59-1P, 2-[4-(4-Chlorobenzoyl)piperidin-1-yl]-3-methyl-6-(pyrimidin-4-yl)-3H-pyrimidin-4-one 503861-31-2P, 2-[3-(4-Fluorobenzoyl)piperidin-1-yl]-3-methyl-6-(pyrimidin-4-yl)-3H-pyrimidin-4-one 503861-32-3P, 2-(3-Benzoylpiperidin-1-yl)-3-methyl-6-(pyrimidin-4-yl)-3H-pyrimidin-4-one 503861-33-4P, 2-[3-(2-Methoxybenzoyl)piperidin-1-yl]-3-methyl-6-(pyrimidin-4-yl)-3H-pyrimidin-4-one 503861-34-5P, 2-[3-(4-Methoxybenzoyl)piperidin-1-yl]-3-methyl-6-(pyrimidin-4-yl)-3H-pyrimidin-4-one | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (drug candidate; preparation of pyrimidinyl pyrimidones that inhibit tau protein kinase 1 useful against neurodegenerative diseases like Alzheimer's disease) | | | | |
| RN | 503860-59-1 CAPLUS | | | | |
| CN | [4,4'-Bipyrimidin]-6(1H)-one, 2-[4-(4-chlorobenzoyl)-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME) | | | | |


10550,299




RN 503861-31-2 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(4-fluorobenzoyl)-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 503861-32-3 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-(3-benzoyl-1-piperidinyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 503861-33-4 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(2-methoxybenzoyl)-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 503861-34-5 CAPLUS
CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[3-(4-methoxybenzoyl)-1-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:709740 CAPLUS
 DN 135:257256
 TI Preparation of 2-amino-3-alkyl-pyrimidones as GSK3 β inhibitors
 IN Almario-Garcia, Antonio; Frost, Jonathan Reid; Li, Adrien-Tak; Ando, Ryoichi; Watanabe, Kazutoshi
 PA Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
 SO Eur. Pat. Appl., 20 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | EP 1136482 | A1 | 20010926 | EP 2000-400800 | 20000323 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO | | | | |
| | CA 2401241 | AA | 20010927 | CA 2001-2401241 | 20010322 |
| | WO 2001070729 | A1 | 20010927 | WO 2001-EP3640 | 20010322 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2001081487 | A5 | 20011003 | AU 2001-81487 | 20010322 |
| | EP 1276738 | A1 | 20030122 | EP 2001-959921 | 20010322 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | JP 2003528095 | T2 | 20030924 | JP 2001-568932 | 20010322 |
| | US 2003187004 | A1 | 20031002 | US 2002-221598 | 20021202 |
| | US 6844335 | B2 | 20050118 | | |
| | US 2005130998 | A1 | 20050616 | US 2005-35264 | 20050113 |
| PRAI | EP 2000-400800 | A | 20000323 | | |
| | WO 2001-EP3640 | W | 20010322 | | |
| | US 2002-221598 | A3 | 20021202 | | |
| OS | MARPAT 135:257256 | | | | |
| IT | 362013-99-8P 362014-00-4P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of 2-amino-3-alkyl-pyrimidones as GSK3 β inhibitors) | | | | |
| RN | 362013-99-8 CAPLUS | | | | |
| CN | 4(3H)-Pyrimidinone, 3-methyl-2-(1-piperidinyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME) | | | | |

10550,299




RN 362014-00-4 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-(1-piperidinyl)-6-(4-pyridinyl)-(2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 362013-99-8

CMF C15 H18 N4 O




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:531662 CAPLUS

DN 133:120343

TI Preparation of arylpyrimidinones and analogs as drugs

IN Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.

PA Amgen Inc., USA

SO U.S., 92 pp., Cont.-in-part of U.S. Ser. No. 976,053, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

PATENT NO.

KIND

DATE


APPLICATION NO.

DATE

10550,299

| | | | | | |
|------|--|----|----------|--|----------|
| PI | US 6096753 | A | 20000801 | US 1997-985346 | 19971204 |
| | ZA 9710727 | A | 19980612 | ZA 1997-10727 | 19971128 |
| | CN 1246857 | A | 20000308 | CN 1997-181558 | 19971204 |
| | TW 520362 | B | 20030211 | TW 1997-86118244 | 19971204 |
| | EP 1314731 | A2 | 20030528 | EP 2002-27704 | 19971204 |
| | EP 1314731 | A3 | 20040102 | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, LT, LV, FI, RO, MK, AL | |
| | EP 1314732 | A2 | 20030528 | EP 2002-27705 | 19971204 |
| | EP 1314732 | A3 | 20040102 | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, AL | |
| | ZA 9710911 | A | 19980605 | ZA 1997-10911 | 19971205 |
| | US 6420385 | B1 | 20020716 | US 2000-504509 | 20000215 |
| | US 6410729 | B1 | 20020625 | US 2000-598740 | 20000621 |
| | US 2003069425 | A1 | 20030410 | US 2002-117552 | 20020403 |
| | US 6610698 | B2 | 20030826 | | |
| | US 2003073704 | A1 | 20030417 | US 2002-128271 | 20020423 |
| | US 6649604 | B2 | 20031118 | | |
| PRAI | US 1996-32128P | P | 19961205 | | |
| | US 1997-50950P | P | 19970613 | | |
| | US 1997-976053 | B2 | 19971121 | | |
| | US 1997-976054 | A | 19971121 | | |
| | EP 1997-954778 | A3 | 19971204 | | |
| | US 1997-984774 | B1 | 19971204 | | |
| | US 1997-985346 | A3 | 19971204 | | |
| | US 2000-504509 | A3 | 20000215 | | |
| | US 2000-598740 | A3 | 20000621 | | |
| OS | MARPAT 133:120343 | | | | |
| IT | 208654-00-6P 208654-61-9P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpyrimidinones and analogs as drugs) | | | | |
| RN | 208654-00-6 CAPLUS | | | | |
| CN | 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[(3S)-3-(phenylmethyl)-1-piperazinyl]-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.




● HCl

RN 208654-61-9 CAPLUS

CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[(3S)-3-(phenylmethyl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1998:394333 CAPLUS
 DN 129:54384
 TI Preparation of arylpyrimidinones and analogs as drugs
 IN Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.; Zablocki, Jeff A.
 PA Amgen Inc., USA; Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.; Zablocki, Jeff A.
 SO PCT Int. Appl., 298 pp.
 CODEN: PIXXD2
 DT Patent
 LA English


FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|------------------|----------|
| PI | WO 9824780 | A2 | 19980611 | WO 1997-US22949 | 19971204 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW | | | | |
| | RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| ZA | 9710727 | A | 19980612 | ZA 1997-10727 | 19971128 |
| CA | 2274093 | AA | 19980611 | CA 1997-2274093 | 19971204 |
| AU | 9855254 | A1 | 19980629 | AU 1998-55254 | 19971204 |
| AU | 735901 | B2 | 20010719 | | |
| EP | 948496 | A2 | 19991013 | EP 1997-951678 | 19971204 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| CN | 1246857 | A | 20000308 | CN 1997-181558 | 19971204 |
| BR | 9713863 | A | 20000314 | BR 1997-13863 | 19971204 |
| NZ | 335992 | A | 20010928 | NZ 1997-335992 | 19971204 |
| JP | 2002514196 | T2 | 20020514 | JP 1998-525902 | 19971204 |
| TW | 520362 | B | 20030211 | TW 1997-86118244 | 19971204 |
| EP | 1314731 | A2 | 20030528 | EP 2002-27704 | 19971204 |
| | EP 1314731 | A3 | 20040102 | | |

10550,299

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, LT, LV, FI, RO, MK, AL
EP 1314732 A2 20030528 EP 2002-27705 19971204
EP 1314732 A3 20040102
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, AL
ZA 9710911 A 19980605 ZA 1997-10911 19971205
MX 9905158 A 20000331 MX 1999-5158 19990603
US 6410729 B1 20020625 US 2000-598740 20000621
US 2003069425 A1 20030410 US 2002-117552 20020403
US 6610698 B2 20030826
PRAI US 1996-32128P P 19961205
US 1997-50950P P 19970613
US 1997-976053 A 19971121
US 1997-976054 A 19971121
EP 1997-954778 A3 19971204
US 1997-984774 B1 19971204
WO 1997-US22949 W 19971204
US 2000-598740 A3 20000621
OS MARPAT 129:54384
IT 208654-00-6P 208654-61-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpyrimidinones and analogs as drugs)
RN 208654-00-6 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[(3S)-3-(phenylmethyl)-1-piperazinyl]-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 208654-61-9 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[(3S)-3-(phenylmethyl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10550,299



=> log y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

ENTRY

25.49

TOTAL

SESSION

193.08

STN INTERNATIONAL LOGOFF AT 08:58:20 ON 16 OCT 2006